Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

The effects of gliclazide, metformin, and acarbose on body composition in patients with newly diagnosed type 2 diabetes mellitus.

Wang H, Ni Y, Yang S, Li H, Li X, Feng B.

Curr Ther Res Clin Exp. 2013 Dec;75:88-92. doi: 10.1016/j.curtheres.2013.10.002.

2.

[A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition].

Shestakova MV, Suhareva OIu, Chernova TO, Shmushkovich IA, Aleksandrov AA, Il'in AV, Dedov II.

Ter Arkh. 2013;85(8):49-55. Russian.

PMID:
24137964
3.

Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.

Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.

Clin Ther. 2011 Dec;33(12):1932-42. doi: 10.1016/j.clinthera.2011.10.014.

PMID:
22078152
4.

Changes in adiponectin level and fat distribution in patients with type 2 diabetes.

Miazgowski T, Dziwura-Ogonowska J, Safranow K, Iskierska K, Widecka K.

Eur J Clin Invest. 2014 Feb;44(2):192-9. doi: 10.1111/eci.12207.

PMID:
24251799
5.

Body composition in adults with newly diagnosed type 2 diabetes: effects of metformin.

Aghili R, Malek M, Valojerdi AE, Banazadeh Z, Najafi L, Khamseh ME.

J Diabetes Metab Disord. 2014 Aug 21;13(1):88. doi: 10.1186/s40200-014-0088-z.

6.

Effects of insulin on body composition in patients with insulin-dependent and non-insulin-dependent diabetes.

Sinha A, Formica C, Tsalamandris C, Panagiotopoulos S, Hendrich E, DeLuise M, Seeman E, Jerums G.

Diabet Med. 1996 Jan;13(1):40-6.

PMID:
8741811
7.

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.

Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, Hanefeld M.

Diabetologia. 2005 Jun;48(6):1093-104.

PMID:
15889234
8.
9.

Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome.

Herrmann BL, Berg C, Vogel E, Nowak T, Renzing-Koehler K, Mann K, Saller B.

Horm Metab Res. 2004 Jan;36(1):54-61.

PMID:
14983408
11.
12.

Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.

Derosa G, Salvadeo SA, D'Angelo A, Ferrari I, Mereu R, Palumbo I, Maffioli P, Randazzo S, Cicero AF.

Curr Med Res Opin. 2009 Mar;25(3):607-15. doi: 10.1185/03007990802711024 .

PMID:
19232035
13.
14.
15.
16.

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TM.

Ann Intern Med. 1994 Dec 15;121(12):928-35.

PMID:
7734015
17.

Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes.

Salman S, Salman F, Satman I, Yilmaz Y, Ozer E, Sengül A, Demirel HO, Karşidağ K, Dinççağ N, Yilmaz MT.

Curr Med Res Opin. 2001;16(4):296-306.

PMID:
11268714
18.

Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.

Kadoglou NP, Kapelouzou A, Tsanikidis H, Vitta I, Liapis CD, Sailer N.

Exp Clin Endocrinol Diabetes. 2011 Feb;119(2):63-8. doi: 10.1055/s-0030-1265174.

PMID:
21031343
19.

Pigment epithelium-derived factor increases in type 2 diabetes after treatment with metformin.

Akın S, Aksoy DY, Cınar N, Aydın K, Karaağaoğlu E, Arıyürek M, Gülçelik NE, Usman A, Gürlek A.

Clin Endocrinol (Oxf). 2012 Dec;77(6):852-6. doi: 10.1111/j.1365-2265.2012.04341.x.

PMID:
22248012
20.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
Items per page

Supplemental Content

Support Center